Victory Capital Management
ELTX icon

Victory Capital Management’s Elicio Therapeutics ELTX Stock Holding History

Victory Capital Management’s Portfolio ELTX Stock Details ELTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-7,684
Closed -$751K – 2797
2021
Q3 		$751K Sell
7,684
-62
-0.8% -$6.7K ﹤0.01% 1975
2021
Q2 		$1.01M Sell
7,746
-516
-6% -$74.4K ﹤0.01% 1893
2021
Q1 		$1.49M Buy
+8,262
New +$1.59M ﹤0.01% 1732

Other funds holding ELTX

NCM
Nantahala Capital Management New Canaan, Connecticut $3B AUM 119.43% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
LSAG
Lake Street Advisors Group Portsmouth, New Hampshire $2.17B AUM 16.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Victory Capital Management's ELTX Position: Q4 2021 in Review

Victory Capital Management sold out of Elicio Therapeutics (ELTX) in Q4 2021, closing a stake of 7,684 shares — an estimated $751K sold.

Victory Capital Management first reported a position in ELTX in Q1 2021 and held it in 3 quarters. The position peaked at $1.49M in Q1 2021. 53 funds tracked by Wall St. Rank hold ELTX as of Q4 2021.

  • Victory Capital Management reported no remaining Elicio Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Victory Capital Management sold 7,684 Elicio Therapeutics shares in Q4 2021, an estimated $751K.
  • Victory Capital Management first reported a position in Elicio Therapeutics in Q1 2021 and held it in 3 quarters.
  • Victory Capital Management's Elicio Therapeutics position peaked at $1.49M in Q1 2021.
  • 53 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q4 2021.

Based on Victory Capital Management's 13F filing for Q4 2021, filed 7 Feb 2022.